Curis (CRIS) investor relations material

Company overview and business model

• Focuses on developing emavusertib, an orally available small molecule inhibitor targeting IRAK4 and FLT3 for hematologic malignancies, including PCNSL, AML, and CLL.

• Emavusertib has received Orphan Drug Designation from the FDA and European Commission for multiple indications.

• Current clinical programs include Phase 1/2 and Phase 2 combination studies in PCNSL and CLL, with regulatory feedback supporting potential accelerated approval pathways.

• Operates under an exclusive collaboration and license agreement with Aurigene Discovery Technologies for emavusertib and other oncology programs.

Financial performance and metrics

• Reported a net loss of $24.2 million for the three months ended March 31, 2026, with an accumulated deficit of $1.3 billion as of that date.

• Cash and cash equivalents totaled $15.0 million as of March 31, 2026, not expected to fund operations beyond 12 months from the filing date.

• Expects to continue generating operating losses and requires substantial additional funding to maintain operations and advance clinical programs.

Use of proceeds and capital allocation

• Net proceeds from the offering (estimated at $13.6 million if fully subscribed) will be used to fund research and development activities, working capital, and general corporate purposes.

• Management retains broad discretion over the allocation of proceeds, with no specific amounts earmarked for particular uses.

• Proceeds may be significantly less if fewer securities are sold, as there is no minimum offering amount.